Clinical Trial

A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 24, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe plaque psoriasis in accordance with the summary of product characteristics (SmPC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-28.
Status change: Recruiting → Active, Not Recruiting 2025-06-23
Trial Details
NCT Number NCT06488170
Lead Sponsor Almirall, S.A.
Conditions Plaque Psoriasis
Enrollment 42 participants
Start Date 2024-04-04
Primary Completion 2026-01 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-24